UNSPSC 51422102: Chloroprednisone

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H25ClO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 564IBO56IP, chemically known as pregna-1,4-diene-3,11,20-trione, 6.alpha.-chloro-17,21-dihydroxy-, 21-acetate but generally known as chloroprednisone, which bears US NIH Compound Identifier 235970. European Medicines Agency schedules Chloroprednisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06192MIG.

UNSPSC 51422102 Chloroprednisone is a Commodity code that in recent state and local procurement activity maps to naloxone procurement, emergency pharmaceutical supplies, and direct-to-manufacturer prescription program capabilities rather than the specific corticosteroid named in the code itself. State and local health agencies, county health departments, and state health and human services commissions use this code family to solicit pharmaceutical products and related dispensing or deactivation systems that support public health missions, emergency preparedness, and pharmacy benefit programs. The issuing bodies span county health departments managing community health initiatives and state-level health agencies overseeing pharmacy benefits for employee populations and safety-net programs.

Recent opportunities include an IFB from Seminole County, Florida (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, and a Request for Information from the Texas Health and Human Services Commission (posted April 3, 2026) gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program to bypass traditional pharmacy benefit managers and group purchasing organizations. The Florida procurement includes standard compliance requirements such as drug-free workplace certification, E-Verify verification, and commercial general liability insurance, with a potential FEMA funding stream introducing federal compliance obligations. The Texas RFI represents preliminary market intelligence gathering to inform future formal solicitation design rather than an immediate procurement award. Activity is concentrated in the South, with Florida and Texas as recent active jurisdictions, though the scope of state and local pharmacy procurement suggests broader geographic distribution not fully captured in the recent opportunities block.